FTC and 13 states sue to block Covetrus's $3.5 billion purchase of Cencora's MWI veterinary unit
The FTC and 13 state attorneys general filed suit in Manhattan federal court on Nov. 13 to stop Covetrus from buying MWI. Covetrus says it will fight.

The Federal Trade Commission has sued to block Covetrus Inc. from acquiring MWI Veterinary Supply Inc. from Cencora Inc. in a $3.5 billion transaction. The agency also named Covetrus's owners, Clayton, Dubilier & Rice LLC and TPG Inc., as it sought to stop the deal. The complaint was filed in the U.S. District Court for the Southern District of New York on Nov. 13, and the attorneys general of 13 states joined it.
What the FTC alleges
According to the complaint, the deal would merge the two largest suppliers in the markets for veterinary clinic distribution and distribution to large corporate accounts. The FTC alleges the combined firm would raise costs for clinics, lower service quality and raise prices for pet owners.
The complaint alleges that Covetrus responded to MWI's aggressive pricing by cutting its own prices and offering rebates through its VetSuite program. It also says competition intensified with the rise of Vetcove, an online platform that lets veterinarians compare prices and use one distributor's offer against the other. The FTC describes the result as an all-out price war.
The agency also argues that other sources of supply do not fill the gap. It alleges specialty distributors, manufacturers, retailers and other fringe suppliers do not meaningfully constrain clinic distributors. The FTC says the combination would be presumptively unlawful.
The Commission voted 2-0 to authorize staff to seek a permanent injunction.
The states' role and the interim order
New York Attorney General Letitia James said the coalition alleges the deal would let Covetrus control more than 50 percent of the relevant markets for veterinary clinic distributors, in violation of both the FTC Act and the Clayton Act. Her office said the companies have agreed to a temporary restraining order that bars closing before December 4, 2026. The coalition intends to seek a preliminary injunction and, ultimately, a ruling that the merger is illegal.
California Attorney General Rob Bonta's office said the investigation was joint with the FTC. It stated that the vast majority of veterinary products in the U.S. move through three national suppliers: Covetrus, MWI and Patterson Veterinary.
Deal terms and the defense
Under the agreement, Cencora would receive $1.25 billion in up-front cash, $800 million in preferred equity and $1.45 billion in common equity in the combined company, leaving it with a 34.3% noncontrolling stake.
Covetrus has rejected the agency's view. It called the FTC's view of the market "narrow and outdated" and said it is prepared to defend the transaction in court. The company points to manufacturers that sell directly to clinics, other national and regional distributors, and online marketplaces.
Reuters reported that J.P. Morgan analysts do not expect the challenge to hurt Cencora's forecast, and expect Cencora to look for alternative MWI transactions if the sale is blocked. The allegations are unproven, and no court has ruled on them.
What this means for in-house counsel
The case involves a challenge to the sale of a business unit to a rival. Sellers may want to assess litigation exposure, cost allocation and cooperation duties in the purchase agreement. They may also want to check how long the outside date lasts and what happens if a court injunction runs past it.
Counsel on deals between the top two players in a concentrated market may want to be wary of assuming that a divestiture offer, or a negotiated fix, will head off litigation. The FTC says the combination would be presumptively unlawful. Deal teams may want to build the economic record on customer switching and alternative suppliers early, since that is the ground Covetrus says it will contest.
State enforcers are co-plaintiffs here, and California's office said its investigation was joint with the FTC. Counsel may want to account for possible state involvement in timelines and regulatory covenants. The temporary restraining order, with its December 4 date, also shows how quickly interim relief can fix the schedule once a complaint is filed. Companies in adjacent healthcare distribution and services markets may want to consider preparing internal documents and customer communications with this kind of scrutiny in mind.
Free weekly email
The Counsel House Brief
The week's most important legal news for general counsel and in-house teams, in one short email.
Counsel House corrects errors promptly. Spot one? Email daniel@counselhouse.org.